Medical news
-
WBDR to go live this January
The World Federation of Hemophilia (WFH) World Bleeding Disorders Registry (WBDR) will go live with the enrollment of the first patient into the patient registry on...
-
WFH closely monitoring Shire and Roche/Genentech patent dispute
The World Federation of Hemophilia has been closely monitoring the developing situation between Shire and Roche/Genentech and their dispute over patent ownership. We will continue...
-
Update: FDA lifts suspension of Fitusiran trial
The United States Food and Drug Administration has agreed to allow Alnylam’s clinical trial of the novel drug Fitusiran to resume. The FDA and Alnylam...
-
Unmet needs and unfinished business in gene therapy
Three experts on gene therapy in hemophilia presented during the final session on day one of the 10th World Federation of Hemophilia Global Forum held...
-
Inhibitors: solving the problem
Three experts on inhibitors in hemophilia opened the first session of the 10th World Federation of Hemophilia (WFH) Global Forum held in Montreal on November...
-
FDA approves Hemlibra for treatment of hemophilia A with inhibitors
Roche has announced that the U.S.A Food and Drug Administration (FDA) has approved Hemlibra (emicizumab-kxwh) for the treatment of hemophilia A with inhibitors. This approval...
-
Report on the Annual Global Survey 2016 now available
The Report on the World Federation of Hemophilia (WFH) Annual Global Survey 2016 is now available in print and online at www.wfh.org/globalsurvey. The report includes...
-
Launch of the WFH Treatment Products eLearning Program
The World Federation of Hemophilia (WFH) is pleased to launch the Treatment Products eLearning Program—a series of educational modules designed for individual self-directed or small-group...
-
A rich program awaits attendees of the WFH 2018 World Congress
The WFH 2018 World Congress is a unique opportunity for the bleeding disorder community to gain further knowledge and insight into improvements to care and...
-
Alnylam Suspends Fitusiran Dosing due to Thrombotic Event in Phase 2 open-label extension study
The WFH was saddened to learn of the death of a hemophilia A patient taking part in the Phase II trial of fitusiran, in development...
